SCHEMBL120991

SCHEMBL120991

[CH2]Oc1ccc(CO)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.54
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
TSHR P16473 1/20 0.43
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
VHL P40337 1/20 0.38
ELOC Q15369 1/20 0.38
ELOB Q15370 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342317 0.78 LTA4H (0.81) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL41775 0.76 TSHR (0.67) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL15417600 0.76 LTA4H (0.62) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL19579519 0.75 LTA4H (0.50) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL728466 0.74 LTA4H (0.54) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL970450 0.74 SMN1; SMN2 (0.45) TSHRCA2
SCHEMBL2163265 0.74 ST14 (0.56) HRH3
SCHEMBL11649743 0.74 HRH3 (0.56) LTA4HPPARGPPARATSHRPRSS1
SCHEMBL17801433 0.74 HRH3 (0.39) TSHRHRH3
SCHEMBL6278014 0.74 LTA4H (0.54) LTA4HPPARGPPARATSHRPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-0241363-B1 NUCLEOSIDE DERIVATIVES AND THEIR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1991-09-25 EP claimed
EP-0241363-A1 Nucleoside derivatives and their use in the synthesis of oligonucleotides COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1987-10-14 EP claimed
JP-6263795-A None JP disclosed
JP-2101099-A None JP disclosed
US-11650499-B2 Photosensitive resin composition, organic EL element barrier rib, and organic EL element SHOWA DENKO K.K. (JP) 2023-05-16 US disclosed
CN-110573240-B Selectively permeable graphene oxide membranes 日东电工株式会社 2022-11-22 CN disclosed
CN-113861268-A Cell penetrating peptides and methods of making and using the same 恩特拉达治疗学股份有限公司 2021-12-31 CN disclosed
CN-106852146-B Cell penetrating peptides and methods of making and using the same 恩特拉达治疗学股份有限公司 2021-08-13 CN disclosed
EP-0467701-A2 Cyclic HIV principal neutralizing determinant peptides MERCK & CO. INC. (US) 1992-01-22 EP disclosed
EP-0467700-A2 Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties MERCK & CO. INC. (US) 1992-01-22 EP disclosed
EP-0467699-A2 Cyclic HIV principal neutralizing determinant peptides MERCK & CO. INC. (US) 1992-01-22 EP disclosed
EP-0452257-A2 Novel platelet-aggregation inhibitors CIBA-GEIGY AG (CH) 1991-10-16 EP disclosed
EP-0394194-A1 Protected amino-acids and process for their preparation CALBIOCHEM-NOVABIOCHEM AG (CH) 1990-10-24 EP disclosed
JP-H02101099-A PEPTIDE NIPPON CHEMIPHAR CO LTD 1990-04-12 JP disclosed
EP-0356395-A2 Flanking peptides and process for their preparation CIBA-GEIGY AG (CH) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA LTA4H 3291/4885PPARG 987/4885PPARA 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.